Co-transplantation of third-party umbilical cord blood-derived MSCs promotes engraftment in children undergoing unrelated umbilical cord blood transplantation

S. H. Lee; M. W. Lee; K. H. Yoo; D. S. Kim; M. H. Son; K. W. Sung; H. Cheuh; S. J. Choi; W. Oh; Y. S. Yang; H. H. Koo

doi:10.1038/bmt.2013.7

Co-transplantation of third-party umbilical cord blood-derived MSCs promotes engraftment in children undergoing unrelated umbilical cord blood transplantation

S. H. Lee, M. W. Lee, K. H. Yoo, D. S. Kim, M. H. Son, K. W. Sung, H. Cheuh, S. J. Choi, W. Oh, Y. S. Yang, H. H. Koo

Pathology

Research output: Contribution to journal › Article › peer-review

44 Scopus citations

Abstract

Success of umbilical cord blood transplantation (UCBT) has been limited by a high rate of graft failure and delayed hematological recovery. It has been postulated that MSCs have hematopoiesis-supportive properties. Therefore, to overcome the limitation of UCBT, third-party UCB-derived MSCs were co-transplanted in recipients receiving unrelated UCBT. Seven patients received UCB and third-party UCB-MSCs. Hematopoietic recovery and transplantation outcomes were compared with historic controls. There was no acute toxicity associated with the infusion of MSCs. The median day to neutrophil engraftment was 19 days in patients, as compared with 24 days in controls (P=0.03). The median day of platelet engraftment was 47 days and 57 days in patients and controls, respectively (P=0.26). In addition, there was no engraftment failure in the MSC group. The incidence of acute and chronic GVHD was comparable between the two groups. However, veno-occlusive disease and TRM did not occur in the MSC group. Third-party UCB-MSCs infusion was safe and feasible. MSCs may also enhance the engraftment of UCBT and prevent rejection. In addition, MSCs may have a role in decreasing TRM. Randomized, controlled trials are required to confirm these results and longer follow-up will determine the effects of MSCs on the risk of relapse.

Original language	English (US)
Pages (from-to)	1040-1045
Number of pages	6
Journal	Bone marrow transplantation
Volume	48
Issue number	8
DOIs	https://doi.org/10.1038/bmt.2013.7
State	Published - Aug 2013

Keywords

Co-transplantation
Engraftment
Mesenchymal stromal cell
Umbilical cord blood transplantation

ASJC Scopus subject areas

Hematology
Transplantation

Access to Document

10.1038/bmt.2013.7

Cite this

Lee, S. H., Lee, M. W., Yoo, K. H., Kim, D. S., Son, M. H., Sung, K. W., Cheuh, H., Choi, S. J., Oh, W., Yang, Y. S., & Koo, H. H. (2013). Co-transplantation of third-party umbilical cord blood-derived MSCs promotes engraftment in children undergoing unrelated umbilical cord blood transplantation. Bone marrow transplantation, 48(8), 1040-1045. https://doi.org/10.1038/bmt.2013.7

@article{83bd5c3c0bb24cae9d44c66b2ab82902,

title = "Co-transplantation of third-party umbilical cord blood-derived MSCs promotes engraftment in children undergoing unrelated umbilical cord blood transplantation",

abstract = "Success of umbilical cord blood transplantation (UCBT) has been limited by a high rate of graft failure and delayed hematological recovery. It has been postulated that MSCs have hematopoiesis-supportive properties. Therefore, to overcome the limitation of UCBT, third-party UCB-derived MSCs were co-transplanted in recipients receiving unrelated UCBT. Seven patients received UCB and third-party UCB-MSCs. Hematopoietic recovery and transplantation outcomes were compared with historic controls. There was no acute toxicity associated with the infusion of MSCs. The median day to neutrophil engraftment was 19 days in patients, as compared with 24 days in controls (P=0.03). The median day of platelet engraftment was 47 days and 57 days in patients and controls, respectively (P=0.26). In addition, there was no engraftment failure in the MSC group. The incidence of acute and chronic GVHD was comparable between the two groups. However, veno-occlusive disease and TRM did not occur in the MSC group. Third-party UCB-MSCs infusion was safe and feasible. MSCs may also enhance the engraftment of UCBT and prevent rejection. In addition, MSCs may have a role in decreasing TRM. Randomized, controlled trials are required to confirm these results and longer follow-up will determine the effects of MSCs on the risk of relapse.",

keywords = "Co-transplantation, Engraftment, Mesenchymal stromal cell, Umbilical cord blood transplantation",

author = "Lee, {S. H.} and Lee, {M. W.} and Yoo, {K. H.} and Kim, {D. S.} and Son, {M. H.} and Sung, {K. W.} and H. Cheuh and Choi, {S. J.} and W. Oh and Yang, {Y. S.} and Koo, {H. H.}",

note = "Funding Information: This study was supported by a grant from the National R&D Program Cancer Control, Ministry for Health, Welfare and Family affairs, Republic of Korea (0520290), and by a grant from the Korea Health 21R&D Project, Ministry of Health, Welfare and Family affairs, Republic of Korea (0405-DB00-0101-0016). This paper was presented at the 2011 BMT tandem meeting in Hawaii.",

year = "2013",

month = aug,

doi = "10.1038/bmt.2013.7",

language = "English (US)",

volume = "48",

pages = "1040--1045",

journal = "Bone marrow transplantation",

issn = "0268-3369",

publisher = "Nature Publishing Group",

number = "8",

}

TY - JOUR

T1 - Co-transplantation of third-party umbilical cord blood-derived MSCs promotes engraftment in children undergoing unrelated umbilical cord blood transplantation

AU - Lee, S. H.

AU - Lee, M. W.

AU - Yoo, K. H.

AU - Kim, D. S.

AU - Son, M. H.

AU - Sung, K. W.

AU - Cheuh, H.

AU - Choi, S. J.

AU - Oh, W.

AU - Yang, Y. S.

AU - Koo, H. H.

N1 - Funding Information: This study was supported by a grant from the National R&D Program Cancer Control, Ministry for Health, Welfare and Family affairs, Republic of Korea (0520290), and by a grant from the Korea Health 21R&D Project, Ministry of Health, Welfare and Family affairs, Republic of Korea (0405-DB00-0101-0016). This paper was presented at the 2011 BMT tandem meeting in Hawaii.

PY - 2013/8

Y1 - 2013/8

N2 - Success of umbilical cord blood transplantation (UCBT) has been limited by a high rate of graft failure and delayed hematological recovery. It has been postulated that MSCs have hematopoiesis-supportive properties. Therefore, to overcome the limitation of UCBT, third-party UCB-derived MSCs were co-transplanted in recipients receiving unrelated UCBT. Seven patients received UCB and third-party UCB-MSCs. Hematopoietic recovery and transplantation outcomes were compared with historic controls. There was no acute toxicity associated with the infusion of MSCs. The median day to neutrophil engraftment was 19 days in patients, as compared with 24 days in controls (P=0.03). The median day of platelet engraftment was 47 days and 57 days in patients and controls, respectively (P=0.26). In addition, there was no engraftment failure in the MSC group. The incidence of acute and chronic GVHD was comparable between the two groups. However, veno-occlusive disease and TRM did not occur in the MSC group. Third-party UCB-MSCs infusion was safe and feasible. MSCs may also enhance the engraftment of UCBT and prevent rejection. In addition, MSCs may have a role in decreasing TRM. Randomized, controlled trials are required to confirm these results and longer follow-up will determine the effects of MSCs on the risk of relapse.

AB - Success of umbilical cord blood transplantation (UCBT) has been limited by a high rate of graft failure and delayed hematological recovery. It has been postulated that MSCs have hematopoiesis-supportive properties. Therefore, to overcome the limitation of UCBT, third-party UCB-derived MSCs were co-transplanted in recipients receiving unrelated UCBT. Seven patients received UCB and third-party UCB-MSCs. Hematopoietic recovery and transplantation outcomes were compared with historic controls. There was no acute toxicity associated with the infusion of MSCs. The median day to neutrophil engraftment was 19 days in patients, as compared with 24 days in controls (P=0.03). The median day of platelet engraftment was 47 days and 57 days in patients and controls, respectively (P=0.26). In addition, there was no engraftment failure in the MSC group. The incidence of acute and chronic GVHD was comparable between the two groups. However, veno-occlusive disease and TRM did not occur in the MSC group. Third-party UCB-MSCs infusion was safe and feasible. MSCs may also enhance the engraftment of UCBT and prevent rejection. In addition, MSCs may have a role in decreasing TRM. Randomized, controlled trials are required to confirm these results and longer follow-up will determine the effects of MSCs on the risk of relapse.

KW - Co-transplantation

KW - Engraftment

KW - Mesenchymal stromal cell

KW - Umbilical cord blood transplantation

UR - http://www.scopus.com/inward/record.url?scp=84881375828&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84881375828&partnerID=8YFLogxK

U2 - 10.1038/bmt.2013.7

DO - 10.1038/bmt.2013.7

M3 - Article

C2 - 23396407

AN - SCOPUS:84881375828

SN - 0268-3369

VL - 48

SP - 1040

EP - 1045

JO - Bone marrow transplantation

JF - Bone marrow transplantation

IS - 8

ER -

Co-transplantation of third-party umbilical cord blood-derived MSCs promotes engraftment in children undergoing unrelated umbilical cord blood transplantation

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this